The development of a combination drug for immunotherapy and trends of the VC and pharmaceutical branch were introduced at the IZB
Ein Dokument
mehr
Storys zum Thema Therapie
-
Sprache:
Englisch
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Sysmex Inostics launches two NGS-based liquid biopsy panels for cancer therapy drug development
Hamburg, Germany and Baltimore, Maryland (ots) - Sysmex Inostics announces the availability of the SafeSEQ Breast Cancer and Head and Neck Cancer Panels along with the SafeSEQ Rapid Custom Development program for circulating tumor DNA (ctDNA) analysis. SafeSEQ is a next-generation sequencing (NGS)-based approach that delivers sensitivity comparable to the clinically ...
mehrSysmex obtains Japanese manufacturing and marketing approval for the first blood-based RAS mutation testing for colorectal cancer
Kobe, Japan (ots) - Sysmex Corporation has obtained Japanese manufacturing and marketing approval for the OncoBEAM(TM) RAS CRC Kit, used for blood-based circulating tumor DNA (ctDNA) molecular testing of mutations in the RAS gene for advanced colorectal cancer patients. With clinically-validated high sensitivity and ...
mehrSysmex Inostics' SafeSEQ ER+/HER2- breast cancer panel demonstrates equivalent sensitivity to OncoBEAM(TM) enhanced digital PCR technology for detection of mutations in circulating tumor DNA
Hamburg/Baltimore (ots) - Recent data presented by Dr. Hope S. Rugo from the University of California San Francisco on behalf of investigators in the Translational Breast Cancer Research Consortium at the American Association of Cancer Research 2019 meeting in Atlanta, Georgia demonstrate how Sysmex Inostics' novel ...
mehrMundipharma EDO GmbH: US FDA Grants Orphan Drug Designation for Tinostamustine in Very Rare Blood Cancer
Basel, Switzerland (ots/PRNewswire) - FOR EX-US MEDICAL AND TRADE MEDIA ONLY - T-cell prolymphocytic leukaemia is an extremely rare and aggressive T-cell leukaemia, with very limited effective treatment options1,2 - Tinostamustine is in very early phase clinical trials to investigate it as a potential future ...
mehrWorld's Largest Import Contract for Pharmaceutical Cannabis within EU
German Farmako secures 50 tonnes of flowers and oils from Polish company Pharmacann Polska over the next four years, generating several hundred Million Euros of revenue. This is the biggest Cannabis contract to date, and the first big contract without the participation of a ...
mehrSysmex Inostics' OncoBEAM(TM) demonstrates clinical validity and superior performance versus pan-cancer NGS for blood-based mutation detection for hepatocellular carcinoma
Hamburg, Germany (ots) - Data recently published in Clinical Cancer Research (http://ots.de/0ZGZkf) the advantages of using an ultra-high sensitivity test for detection of mutations which may predict therapeutic efficacy for hepatocellular carcinoma (HCC). Sysmex Inostics' OncoBEAM technology, a highly clinically ...
mehrSysmex Inostics OncoBEAM(TM) circulating tumor DNA technology demonstrates superior response prediction for advanced pancreatic cancer over standard-of-care protein biomarkers
Hamburg, Germany (ots) - Recent data published in Annals of Oncology (https://academic.oup.com/annonc/advance-article/doi/10.1093/annonc/mdy417/5139593) from a study conducted by Sysmex Inostics and University of Munich indicate that circulating tumor DNA (ctDNA) may offer clinicians higher-resolution information ...
mehrTwo-pronged approach - Novel combined therapy tackles excess fatty tissue
A new combined therapy for obesity and diabetes has been shown to suppress the appetite and at the same time increase energy expenditure. Scientists from the Helmholtz Zentrum München and the Technical University of Munich (TUM), partner institutions of the German Center for ...
mehrSysmex Inostics' OncoBEAM(TM) platform demonstrates superior detection of clinically-relevant mutations for therapy selection and molecular monitoring for lung and colon cancers
Hamburg, Germany (ots) - Data presented at the European Society of Medical Oncology (ESMO) 2018 meeting in Munich, Germany by three clinical oncology research groups demonstrate the importance of a highly sensitive test for detection of clinically-relevant mutations present in circulating tumor DNA (ctDNA) derived ...
mehrTechnische Universität München
Test predicts outcome of hay fever therapies
TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 22731 - email: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/detail/article/35000/ NEWS RELEASE Test predicts outcome of hay fever therapies Allergy researchers look into molecular processes in hyposensitization to pollen Allergen-specific immunotherapy can make everyday life ...
mehrSysmex Inostics' OncoBEAM(TM) liquid biopsy technology demonstrates utility for clinical management of melanoma patients undergoing treatment with targeted therapy and immune checkpoint inhibitors
Hamburg, Germany (ots) - Sysmex Inostics, a pioneer in blood-based circulating tumor DNA (ctDNA) analysis and molecular diagnostics for oncology, is pleased to announce publication of a study in the Journal of Molecular Oncology highlighting the important clinical value of blood-based ctDNA mutation testing to ...
mehr
Vorherige1234